These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4297170)

  • 1. [Examination of foot-and-mouth disease virus strains with regard to their suitability for modified virus vaccine preparation].
    Wittmann G; Ahl R; Bauer K
    Bull Off Int Epizoot; 1966; 65(11):1901-20. PubMed ID: 4297170
    [No Abstract]   [Full Text] [Related]  

  • 2. [Report on the characteristics of foot-and-mouth disease virus capable of being used as live vaccines].
    Asso J; Paraf A; Aynaud JM; Lucas A; Dhennin L; Gayot G
    Bull Off Int Epizoot; 1966; 65(11):1929-36. PubMed ID: 4296532
    [No Abstract]   [Full Text] [Related]  

  • 3. An early stage in the comparison of methods of modification of a field strain of foot-and-mouth disease, type A (Turkey 19-64).
    Quinones-Sowerby C; Knight EH; Taylor DI; McGrath T
    Bull Off Int Epizoot; 1966; 65(11):2071-89. PubMed ID: 4296535
    [No Abstract]   [Full Text] [Related]  

  • 4. [Survival in cattle of the modified foot-and-mouth disease virus].
    Auge de Mello P; Honigman MN; Fernandes MV
    Bull Off Int Epizoot; 1966; 65(11):2091-106. PubMed ID: 4296536
    [No Abstract]   [Full Text] [Related]  

  • 5. [Strains of foot-and-mouth viruses which can be used for live vaccines].
    Onoufriev V
    Bull Off Int Epizoot; 1966; 65(11):1967-73. PubMed ID: 5994042
    [No Abstract]   [Full Text] [Related]  

  • 6. [Methods of testing of safety of the anti-foot-and-mouth disease vaccine].
    Dannacher G; Fédida M; Coudert M; Perrin M
    Dev Biol Stand; 1976; 35():271-8. PubMed ID: 198294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The suitability of a rolled BHK21 monolayer system for the production of vaccines against the SAT types of foot-and-mouth disease virus. I. Adaptation of virus isolates to the system, immunogen yields achieved and assessment of subtype cross reactivity.
    Esterhuysen JJ; Thomson GR; Ashford WA; Lentz DW; Gainaru MD; Sayer AJ; Meredith CD; Janse van Rensburg D; Pini A
    Onderstepoort J Vet Res; 1988 Jun; 55(2):77-84. PubMed ID: 2839810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further information on the survival of modified foot-and-mouth disease virus in cattle.
    Augé de Mello P; Honigman MN; Fernandes MV; Gomes I
    Bull Off Int Epizoot; 1970; 73(5):489-505. PubMed ID: 4337797
    [No Abstract]   [Full Text] [Related]  

  • 9. Standards for modified strain vaccines in foot-and-mouth disease.
    Brooksby JB
    Bull Off Int Epizoot; 1966; 65(11):1941-7. PubMed ID: 5994041
    [No Abstract]   [Full Text] [Related]  

  • 10. [Immunobiological properties of strains of foot-and-mouth disease virus multiplying in cell cultures].
    Efimov NI; Siusiukin AA; Shvetsova RV; Serodzhev AT
    Veterinariia; 1975 May; (5):53-5. PubMed ID: 174272
    [No Abstract]   [Full Text] [Related]  

  • 11. [Study of alkylating agents for the inactivation of foot-and-mouth disease virus and the preparation of a new inactivated vaccine].
    Durand M; Guilloteau B; Giraud M; Guerche M; Pesson M; Prunet P
    Bull Off Int Epizoot; 1968; 69(3):429-65. PubMed ID: 4303692
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effect of temperature during passage on the properties of attenuated foot and mouth disease virus].
    Urvantsev NM; Siusiukin AA; Sergeev VA; Prokhorov VV
    Veterinariia; 1971 Jan; 1():37-9. PubMed ID: 4325013
    [No Abstract]   [Full Text] [Related]  

  • 13. [Studies on the suitability of tissue culture neutralization tests in the government etesting of adsorbed foot-and mouth disease vaccines. 1. The content of neutralizing antibody in the serum of cattle after vaccination with adsorbed vaccine against type O2 virus in comparison with the direct immunity testing in cattle].
    Rüting E; Seils H; Weyhe D; Benndorf E
    Arch Exp Veterinarmed; 1969; 23(4):827-38. PubMed ID: 4319494
    [No Abstract]   [Full Text] [Related]  

  • 14. [The role of foot-and-mouth disease antibodies of sera in BHK 21 industrial cell cultures used for the production of vaccines].
    Mammerickx M; Leunen J
    Bull Off Int Epizoot; 1968; 69(3):487-96. PubMed ID: 4303694
    [No Abstract]   [Full Text] [Related]  

  • 15. [Safety of foot-and-mouth disease vaccines in cell cultures].
    Tekerlekov P; Dilovski M; Gergov P; Nikolova E
    Vet Med Nauki; 1982; 19(1):21-5. PubMed ID: 6287707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential of recombination for the production of foot-and-mouth disease virus vaccine strains.
    McCahon D; King AM; Slade WR; Skinner HH; Haresnape J
    Dev Biol Stand; 1980; 46():223-30. PubMed ID: 6244999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities of biophysicochemical antigen control in vaccine production using foot-and-mouth disease virus as an example (review)].
    Liebermann H; Kwasniowski W; Strebelow G
    Arch Exp Veterinarmed; 1988 Mar; 42(2):165-73. PubMed ID: 2840042
    [No Abstract]   [Full Text] [Related]  

  • 18. [Apropos of the conclusions (Point I, Section E) of the 11th conference of the Permanent Commission on Foot-and-Mouth Disease of the International Office of Epizootic Diseases in Paris].
    Röhrer H
    Bull Off Int Epizoot; 1966; 65(11):1921-8. PubMed ID: 5994040
    [No Abstract]   [Full Text] [Related]  

  • 19. [Studies on live foot-and-mouth disease virus vaccines].
    Palacios CA
    Bol Oficina Sanit Panam; 1968 May; 64(5):386-410. PubMed ID: 4300940
    [No Abstract]   [Full Text] [Related]  

  • 20. [Saponin vaccine from the Ai variant of lapinized foot-and-mouth disease virus].
    Andreev EV; Boĭko AA; Lutsevich FF; Filatov IP; Mikhaĭliuk AP
    Veterinariia; 1968 Jan; 45(1):28-31. PubMed ID: 4312579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.